Structure Therapeutics, Inc. (GPCR)
49.72
+0.71
(+1.45%)
USD |
NASDAQ |
Aug 25, 13:31
Structure Therapeutics Net Income (Quarterly) : -106.33M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -106.33M |
| March 31, 2026 | -76.19M |
| December 31, 2025 | 33.15M |
| September 30, 2025 | -65.80M |
| June 30, 2025 | -61.88M |
| March 31, 2025 | -46.90M |
| December 31, 2024 | -36.35M |
| September 30, 2024 | -34.26M |
| June 30, 2024 | -26.00M |
| Date | Value |
|---|---|
| March 31, 2024 | -25.99M |
| December 31, 2023 | -24.67M |
| September 30, 2023 | -23.86M |
| June 30, 2023 | -23.03M |
| March 31, 2023 | -17.94M |
| December 31, 2022 | -11.86M |
| June 30, 2022 | -13.88M |
| March 31, 2022 | -13.10M |
| December 31, 2021 | -15.34M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.095B |
| Novo Nordisk A/S | 3.265B |
| Pfizer Inc. | -246.00M |
| Tarsus Pharmaceuticals, Inc. | -18.55M |
| Johnson & Johnson | 5.534B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 106.33M |
| EPS Diluted (Quarterly) | -1.464 |
| Enterprise Value | 2.154B |
| Earnings Yield | -6.20% |
| Normalized Earnings Yield | -6.440 |